Creagan E T, Ingle J N, Ahmann D L, Green S J
Cancer. 1982 Apr 1;49(7):1353-4. doi: 10.1002/1097-0142(19820401)49:7<1353::aid-cncr2820490707>3.0.co;2-4.
Seventeen patients with disseminated malignant melanoma received a daily oral regimen of tamoxifen, 100 mg/m2. All patients had prior chemotherapy and predominantly visceral involvement. None of the patients had an objective regression and most (71%) had progressive disease at the time of first reassessment. Moderate to severe nausea occurred in 24% of patients. In the dose and schedule used in this study, tamoxifen is ineffective in patients with advanced malignant melanoma and prior chemotherapy exposure.
17例播散性恶性黑色素瘤患者接受了他莫昔芬每日口服方案治疗，剂量为100mg/m²。所有患者此前均接受过化疗，且主要为内脏受累。在首次重新评估时，没有患者出现客观缓解，大多数患者（71%）病情进展。24%的患者出现了中度至重度恶心。在本研究使用的剂量和疗程下，他莫昔芬对既往接受过化疗的晚期恶性黑色素瘤患者无效。
